STING1 and breast cancer: Patients with high STING expression at baseline tended to have a poorer prognosis of recurrence‐free survival (RFS), distant recurrence‐free survival (DRFS), and breast cancer‐specific survival (BCSS), although the differences in survival between those with high and low STING expression were not significant (Figure 3A–C).